HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Romania’s OTC Market in 2018: Colds And Flu Epidemic Help Boost Sales By 14%

Executive Summary

Romanian self-care industry association, RASCI, provides HBW Insight with an exclusive viewpoint on the country's OTC market in 2018. 

You may also be interested in...



Phoenix pins its hopes on Romania

Pan-European wholesaler and retailer Phoenix expects to grow faster than the European pharmaceutical market as a whole for the rest of its 2018-2019 financial year driven by recent acquisitions in Romania. “

Romanian OTC market put under the microscope

Consumer healthcare firms operating in Romania could soon have to navigate a host of regulatory changes after the country’s Competition Council launched an investigation into the “production and marketing of non-prescription medicines and food supplements”.

Phoenix prepares for a digital future

Digitalisation is becoming a key strategic focus for Phoenix, according to the firm’s chief executive officer Oliver Windholz.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS148619

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel